The University of Southampton
University of Southampton Institutional Repository

Immunotherapy for Alzheimer's disease and other dementias

Immunotherapy for Alzheimer's disease and other dementias
Immunotherapy for Alzheimer's disease and other dementias
Objective: The aim of this article is to review the role of immunotherapy in the removal of proteins which accumulate abnormally in neurodegenerative disorders associated with dementia, in particular amyloid-beta accumulation in Alzheimer's disease.
Results: In both transgenic mouse models and in two trials of amyloid-beta immunotherapy for human Alzheimer's disease, active immunization with amyloid-beta 1-42 results in the removal of amyloid-beta plaques from the cerebral cortex associated with, in the mouse models, improvement in cognitive function. Cerebral amyloid angiopathy and neurofibrillary tangles persist, however, and there is also concern about T lymphocyte immune reactions in the meninges in the human cases. Active immunization schedules are being developed to minimize T lymphocyte reactions and to maximize antibody production and passive immunization protocols are being devised. Immunotherapy for removal of the proteins which accumulate in other neurodegenerative disorders associated with dementia such as prion proteins and alpha-synuclein are in the early stages of development.
Conclusion: Dementias in the elderly are an increasing medical, social and economic problem and current treatments are only effective. In the majority of dementias, proteins accumulate within cells and in the extracellular compartments of the brain. In the most common dementia, Alzheimer's disease, amyloid-beta accumulates as plaques in the extracellular space of the grey matter and in artery walls as cerebral amyloid angiopathy and tau protein accumulates as neurofibrillary tangles within neurons
plaque removal, immunization, a-beta immunotherapy, prion, antibodies, pathogenesis, disease, prion disease, pathology, dementia, disorder, mouse model, trial, antibody, alzheimer's disease, cerebral amyloid angiopathy, immune-response, peptide, model, immunotherapy, treatment, disorders, interstitial fluid, neurodegenerative diseases
0362-5664
22-27
Boche, D.
bdcca10e-6302-4dd0-919f-67218f7e0d61
Nicoll, JAR.
88c0685f-000e-4eb7-8f72-f36b4985e8ed
Weller, RO.
4a501831-e38a-4d39-a125-d7141d6c667b
Boche, D.
bdcca10e-6302-4dd0-919f-67218f7e0d61
Nicoll, JAR.
88c0685f-000e-4eb7-8f72-f36b4985e8ed
Weller, RO.
4a501831-e38a-4d39-a125-d7141d6c667b

Boche, D., Nicoll, JAR. and Weller, RO. (2006) Immunotherapy for Alzheimer's disease and other dementias. Clinical Neuropharmacology, 29 (1), 22-27.

Record type: Article

Abstract

Objective: The aim of this article is to review the role of immunotherapy in the removal of proteins which accumulate abnormally in neurodegenerative disorders associated with dementia, in particular amyloid-beta accumulation in Alzheimer's disease.
Results: In both transgenic mouse models and in two trials of amyloid-beta immunotherapy for human Alzheimer's disease, active immunization with amyloid-beta 1-42 results in the removal of amyloid-beta plaques from the cerebral cortex associated with, in the mouse models, improvement in cognitive function. Cerebral amyloid angiopathy and neurofibrillary tangles persist, however, and there is also concern about T lymphocyte immune reactions in the meninges in the human cases. Active immunization schedules are being developed to minimize T lymphocyte reactions and to maximize antibody production and passive immunization protocols are being devised. Immunotherapy for removal of the proteins which accumulate in other neurodegenerative disorders associated with dementia such as prion proteins and alpha-synuclein are in the early stages of development.
Conclusion: Dementias in the elderly are an increasing medical, social and economic problem and current treatments are only effective. In the majority of dementias, proteins accumulate within cells and in the extracellular compartments of the brain. In the most common dementia, Alzheimer's disease, amyloid-beta accumulates as plaques in the extracellular space of the grey matter and in artery walls as cerebral amyloid angiopathy and tau protein accumulates as neurofibrillary tangles within neurons

Full text not available from this repository.

More information

Published date: January 2006
Additional Information: (Reprinted from Curr. Opin. Neurol. vol 118, 720-725, 2005)
Keywords: plaque removal, immunization, a-beta immunotherapy, prion, antibodies, pathogenesis, disease, prion disease, pathology, dementia, disorder, mouse model, trial, antibody, alzheimer's disease, cerebral amyloid angiopathy, immune-response, peptide, model, immunotherapy, treatment, disorders, interstitial fluid, neurodegenerative diseases

Identifiers

Local EPrints ID: 62329
URI: https://eprints.soton.ac.uk/id/eprint/62329
ISSN: 0362-5664
PURE UUID: 81b8c7d4-f6fb-494b-8b05-0dd249be76aa
ORCID for D. Boche: ORCID iD orcid.org/0000-0002-5884-130X
ORCID for JAR. Nicoll: ORCID iD orcid.org/0000-0002-9444-7246

Catalogue record

Date deposited: 18 Sep 2008
Last modified: 14 Mar 2019 01:47

Export record

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×